To include your compound in the COVID-19 Resource Center, submit it here.

FDA warns Celltrion of GMP violations at Inflectra facility

FDA issued a warning letter to Celltrion Inc. (KOSDAQ:068270) on Jan. 26 identifying "significant violations" of GMP regulations regarding production of

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE